Prostate cancer is the second most common cancer in men, affecting millions worldwide. Over the past few years, significant advancements have been made in understanding the disease’s biology, leading to improved diagnostic methods and more effective therapies. This article provides an overview of the current state of prostate cancer therapy, touching on both traditional and emerging treatments and the challenges faced in providing personalised care for patients.
Conventional Treatments
Emerging Treatments
Challenges in Personalised Care
Despite the advancements in prostate cancer therapy, challenges remain in providing personalised care for patients. The heterogeneity of the disease, variable treatment responses, and resistance mechanisms complicate the selection of optimal therapies. Moreover, access to cutting-edge treatments can be limited due to high costs and availability in certain regions.
[wpseo_breadcrumbs]
Radiotheranostics in prostate cancer enables precise diagnosis and targeted treatment, improving patient outcomes significantly.
Radiotheranostics in Prostate Cancer: A New Frontier in Precision Treatment Read Post »
Radioactive cancer therapies utilise targeted radiation to damage tumour DNA, halting their growth and preventing further spread.
Radioactive Cancer: Harnessing Radiation in the Fight Against Malignancy Read Post »
Alpha particles provide precise cancer treatment by delivering high-energy radiation, targeting tumour cells while sparing healthy tissue.
The Role of Alpha Particles in Radiotheranostics Read Post »
The Science Behind Tactile Imaging Medical diagnostics have seen remarkable advancements over the years, with imaging technologies playing a pivotal
Tactile Imaging: Transforming Diagnostic Medicine Through the Sense of Touch Read Post »
Targeted Alpha Radionuclide Therapy precisely delivers potent alpha particles to tumors, maximising efficacy while sparing healthy tissues.
The Role of Targeted Alpha Radionuclide Therapy in Modern Oncology Read Post »
Copper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
Radiotheranostics merges diagnostics and therapy, offering targeted cancer treatment amidst challenges like high costs and need for specialised facilities.
Revolutionising Cancer Care: The Promise and Challenges of Radiotheranostics Read Post »
225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment Read Post »
225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
Lasers in medicine offer revolutionary precision and versatility, significantly advancing healthcare through diverse, minimally invasive applications.
Lighting the Way in Healthcare: The Transformative Role of Lasers in Medicine Read Post »
Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities.
Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review Read Post »
Posluma (Flotufolastat F-18) offers precise PET imaging for detecting PSMA-positive prostate cancer lesions.
Radium-223 dichloride, a targeted alpha therapy, effectively treats castration-resistant prostate cancer with bone metastases, improving patients’ overall survival.
Lutetium-177 Vipivotide Tetraxetan – Pluvicto: Radiopharmaceutical for targeted cancer therapy. Innovative, promising, precise, advanced, therapeutic.
Prostate cancer’s global impact persists; mCRPC, demanding advanced strategies, finds hope in 177Lu-PSMA targeted radioligand therapy.
Fluorine-18 Piflufolastat, a novel radiotracer, enables precise imaging of prostate cancer, enhancing diagnostic accuracy and facilitating personalied, targeted treatment approaches.
Fluorine-18 Piflufolastat: An Innovative Approach to Prostate Cancer Imaging Read Post »
Fluorine-18 Flucicovine (Axumin) improves prostate cancer detection, enabling accurate diagnosis and targeted treatments with PET imaging.
Topics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.
Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy Read Post »
